Patricia LoRusso

May 30, 2024 | newswise.com | Patricia LoRusso

Breast cancer that has spread to other parts of the body (metastatic) is particularly hard to treat. New research from Yale Cancer Center reveals first-of-its-kind data from a phase I study in patients with hormone receptor positive HER2-negative metastatic breast cancer. The results, which assess the safety and efficacy of a treatment known as PF-07248144, offer new hope for treating this aggressive type of breast cancer.

Apr 1, 2024 | newswise.com | Roy S. Herbst |Patricia LoRusso

Yale Cancer Center Experts, Scientists to Share Vision and Research at Leading ConferenceOne of the largest global gatherings of cancer experts begins Friday in San Diego, at the annual meeting of the American Association of Cancer Research (AACR). The five-day session (April 5-10), themed as “Inspiring Science. Fueling Progress.

Jun 8, 2023 | newswise.com | Eric S. Winer |Patricia LoRusso

Newswise — By their early 20s, two of Yale’s most prominent cancer experts had each been immersed in healthcare battles for many years. Few people would have been surprised if they chose careers outside of healthcare. Instead, Drs. Eric Winer and Patricia LoRusso chose to pursue cancer care and research as their work. Both are now leaders of two of the country’s most prestigious organizations for cancer professionals.

May 31, 2023 | ascopubs.org | Erika P. Hamilton |Jenny Zheng |Patricia LoRusso |Natasha Homji Mishra

Background: KAT6A and KAT6B regulate gene transcription via acetylation of histone H3K23 and their dysregulation drives lineage-specific gene expression in cancer. We report dose escalation data from the first-in-human phase 1 (Part 1A and 1B; NCT04606446) study of the KAT6-selective inhibitor PF-07248144. Methods: Part 1A (monotherapy dose escalation) enrolled patients (pts) with advanced/metastatic ER+/HER2− breast cancer (mBC), CRPC, or NSCLC, resistant/intolerant to standard therapy.